RecruitingPhase 2NCT04074135

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors


Sponsor

National Cancer Institute (NCI)

Enrollment

740 participants

Start Date

Jun 2, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Background: People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect them. This may help them design better future treatment and care for people with VHL disease. Objective: To better understand VHL disease that affects the pancreas and to test whether adding a certain type of scan (68-Gallium DOTATATE PET/CT) can further detect tumors. Eligibility: People ages 12 and older with VHL that causes tumors and cysts to grow in the pancreas Design: Participants will be screened with their medical records and imaging studies. Participants will have an initial evaluation: Participants will have their body examined by different doctors. This will depend on what types of symptoms they have. Participants will have blood and urine tests Participants will have images made of their body using one or more machines: They made have a CT or PET/CT scan in which they lie on a table that moves through a big ring. They may have an MRI in which they lie on a table that moves into a big tube. They may have an ultrasound that uses a small stick that produces sound waves to look at the body. After the first visit, participants will be asked to return to the NIH. Some of the tests performed at the first visit will be repeated. Depending on their disease status, visits will be once a year or every 2 years for life.


Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking the natural history of pancreatic tumors in people with Von Hippel-Lindau (VHL) disease — a rare inherited condition that causes tumors and cysts to grow in various organs, including the pancreas. Researchers want to understand how these pancreatic growths develop over time to improve management and treatment decisions. **You may be eligible if...** - You have been diagnosed with VHL disease (either by genetic testing or clinical criteria) - You have at least one pancreatic finding (cyst, solid lesion, or tumor) on any imaging scan - You are 12 years or older - You are willing and able to sign informed consent **You may NOT be eligible if...** - You are unable to undergo imaging studies needed for follow-up - You cannot provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68-Gallium DOTATATE

68-Gallium DOTATATE, to be used in yearly PET/CT research scans


Locations(1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04074135


Related Trials